Group 1 - AstraZeneca's investigational drug, Anselamimab, failed to meet primary endpoints in its Phase III trial for AL amyloidosis, which aimed to extend patient survival and reduce heart-related hospitalizations, leading to a gap between expectations and results [1][2] - Despite the overall trial data not meeting expectations, AstraZeneca's rare disease division CEO highlighted that some patient groups showed positive treatment responses, indicating potential value in further analysis [1][2] - AL amyloidosis treatment currently relies on CD38 monoclonal antibodies like Daratumumab, which has shown improved complete response rates and organ response rates compared to traditional chemotherapy, but existing therapies have limitations [2] Group 2 - The competitive landscape for new drug development in AL amyloidosis is intense, with other candidates like CAEL-101 showing potential but requiring further validation in Phase III trials [3] - AstraZeneca plans to continue data analysis for Anselamimab and explore its applicability in more precise patient populations, aiming for synergistic effects with existing therapies to improve patient outcomes [3]